Published in JAMA · View the paper (DOI)
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
Coverage from 2 institutions